TMEM109

Across TCGA pan-cancer cohorts, TMEM109 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TMEM109’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMEM109 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM109 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where TMEM109 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM109 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.383	<.001	7	view →
PDAC	All	All	−0.484	<.001	5	view →
HNSC	Female	All	−0.562	.008	3	view →
LSCC	All	All	+0.145	<.001	3	view →
OV	All	All	−0.428	.003	2	view →
COAD	All	IV	+0.310	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TMEM109–CCRCC

Open the CCRCC breakdown →